Evogene Reports 86% Q1 Revenue Plunge, $5.87M Net Loss; Raises Capital via Warrants
EVGN is trading near its 52-week low of $0.683 (5.4% above the low).
Summary
Evogene reported a Q1 GAAP net loss of $5.87 million and revenue of $0.334 million, representing an 86% year-over-year decline. This follows the Q4 and full-year 2025 results reported in March, which showed a 37% reduction in annual operating expenses. The massive revenue drop and substantial net loss are highly concerning for a company with a small market capitalization, indicating severe operational challenges. The company also raised capital via warrants, which provides funding but could be dilutive.
At the time of this announcement, EVGN was trading at $0.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.7M. The 52-week trading range was $0.68 to $2.42. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Wiseek News.